Skip to main content
Premium Trial:

Request an Annual Quote

Axiogenesis Inks Sublicensing Agreement with GE Healthcare for Stem Cell IP

NEW YORK (GenomeWeb) –Axiogenesis today announced it has sublicensed patents from GE Healthcare to allow the German cell supplier to commercialize technologies based on human induced pluripotent stem cells (iPSCs).

Under the terms of the agreement, GE Healthcare will sublicense patents for the use of human iPSCs which will enable Axiogenesis to develop cellular assays and stem cell-derived models of disease for use in drug discovery and toxicity screening.

Cologne, Germany-based Axiogenesis said in a statement that the agreement strengthens its ability to offer its customers freedom-to-operate with regard to its iPSC-derived products, which include cardiomyocytes, peripheral and dopaminergic neurons, and connective tissues such as cardiac fibroblasts and astrocytes.

The sublicensed patents provide Axiogenesis' in vitro assays for preclinical drug development a "more efficient path to market," Axiogenesis CEO Heribert Bohlen said in a statement.

GE Healthcare acquired the rights to sublicense the patents in a deal with BioTime signed in December 2014.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.